Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Q32 Bio Inc.QTTB · Entity 5594 | Director | June 12, 2026 | July 22, 2026 |
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Director | June 03, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Q32 Bio Inc.
Report date June 12, 2026 · Filed July 22, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2036-06-11 | Direct | 10,826 |
Reported balance
After 2026-06-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 10,826 · Balance 10,826 F1: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F2: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
F2: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Stoke Therapeutics, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.46 · Expires 2036-06-02 | Direct | 17,786 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 17,786 · Balance 17,786 F1: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akouos, Inc.
Report date November 30, 2022 · Filed December 02, 2022
Section 16 reporting ended · disclosed 2022-12-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-30 transaction · row 1
1 source rowRow 1 · 2022-11-30 · Other · Disposed 26,930 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, these shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for (i) $12.50 per Share, net to the stockholder in cash, without interest (the "Cash Consideration") and less any applicable tax withholding, plus [Continued on Note 2] F2: [Continuation of Note 1] (ii) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.38 · Expires 2030-05-11 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-12-01 · Disposition to issuer · Disposed 12,100 · Balance 0 F3: At the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option to purchase Shares having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by (B) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option and (y) one CVR for each Share subject to such option immediately prior to the Effective Time (without regard to vesting). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.21 · Expires 2032-06-22 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-12-01 · Disposition to issuer · Disposed 16,000 · Balance 0 F3: At the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option to purchase Shares having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by (B) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option and (y) one CVR for each Share subject to such option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, these shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for (i) $12.50 per Share, net to the stockholder in cash, without interest (the "Cash Consideration") and less any applicable tax withholding, plus [Continued on Note 2]
F2: [Continuation of Note 1] (ii) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A.
F3: At the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option to purchase Shares having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by (B) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option and (y) one CVR for each Share subject to such option immediately prior to the Effective Time (without regard to vesting).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 16, 2026 20:30 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 9,810 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-272697 · ownership.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,810 Underlying: Common Stock · 9,810 shares Expires 2036-06-11 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| June 12, 2026 Filed Jul 22, 2026 00:40 UTC Amendment | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 10,826 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001193125-26-310983 · ownership.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,826 Underlying: Common Stock · 10,826 shares Expires 2036-06-11 F1 · shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. F1 · derivative.underlying_shares: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F1 · balance_after: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:33 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 17,786 | $0.00 Strike: $29.46 | $0.00 |
DisclosureSEC source: 0001586226-26-000004 · form4-06052026_080612.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,786 Underlying: Common Stock · 17,786 shares Expires 2036-06-02 F1 · derivative.exercise_date: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:57 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,955 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001586226-26-000002 · form4-03122026_080323.xml · derivative · entry 3 TZIANABOS ARTHUR · CIK 0001586226 · Director · Interim Executive Chair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,696 Underlying: Common Stock · 3,955 shares Expires 2034-03-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Effective October 6, 2025, this option became fully vested and exercisable. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:57 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 4,355 | $40.00 | $174,214.37 |
DisclosureSEC source: 0001586226-26-000002 · form4-03122026_080323.xml · nonDerivative · entry 2 TZIANABOS ARTHUR · CIK 0001586226 · Director · Interim Executive Chair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,339 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.095 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:57 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 3,955 | $8.33 | $32,945.15 |
DisclosureSEC source: 0001586226-26-000002 · form4-03122026_080323.xml · nonDerivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director · Interim Executive Chair 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,694 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 23, 2025 Filed Oct 28, 2025 01:16 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 53,521 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001193125-25-251981 · ownership.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,521 Underlying: Common Stock · 53,521 shares Expires 2035-10-22 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| March 20, 2025 Filed Mar 20, 2025 22:18 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantStock Option (Right to Buy) · Derivative | 122,651 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001415889-25-008714 · form4-03202025_100333.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director · Interim Executive Chair 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,651 Underlying: Common Stock · 122,651 shares Expires 2035-03-19 F1 · derivative.exercise_date: The option vests ratably as to 1/12 of the total award on the monthly anniversary of the grant date, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:01 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 12,767 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0000950170-25-028265 · ownership.xml · derivative · entry 4 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,767 Underlying: Common Stock · 12,767 shares Expires 2034-03-24 F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:01 UTC | Q32 Bio Inc. QTTB · Entity 5594 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,767 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0000950170-25-028265 · ownership.xml · derivative · entry 3 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,767 shares Expires 2034-03-24 F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:01 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 25,674 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0000950170-25-028265 · ownership.xml · derivative · entry 2 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,674 Underlying: Common Stock · 25,674 shares Expires 2026-04-22 F3 · derivative.exercise_price: The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 27, 2025 11:01 UTC | Q32 Bio Inc. QTTB · Entity 5594 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,674 | $0.00 Strike: $7.09 | $0.00 |
DisclosureSEC source: 0000950170-25-028265 · ownership.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,674 shares Expires 2026-04-22 F1 · kind: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:19 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,639 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0001415889-24-015965 · form4-06072024_080651.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,639 Underlying: Common Stock · 7,639 shares Expires 2034-06-04 F1 · derivative.exercise_date: The option shall vest in full on the earlier of: (i) June 5, 2025 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 21:43 UTC | Q32 Bio Inc. QTTB · Entity 5594 | GrantStock Option (Right to Buy) · Derivative | 12,767 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0000950170-24-037404 · ownership.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,767 Underlying: Common Stock · 12,767 shares Expires 2034-03-24 F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 25, 2024 Filed Aug 14, 2024 20:05 UTC | Q32 Bio Inc. QTTB · Entity 5594 | Exercise / conversionRestricted Stock Units · Derivative | 1,095 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-096986 · ownership.xml · derivative · entry 3 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,095 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer Common Stock. F2 · shares: The Issuer effected a 1-for-18 reverse stock split of its Common Stock on March 25, 2024. The amounts reported on this Form 4 have been adjusted to reflect the reverse stock split. F4 · derivative.exercise_date: The restricted stock units vested in three equal installments, with the final installment vested on March 25, 2024. The restricted stock units had no expiration date. F4 · derivative.expiration_date: The restricted stock units vested in three equal installments, with the final installment vested on March 25, 2024. The restricted stock units had no expiration date. Read SEC document |
| March 25, 2024 Filed Aug 14, 2024 20:05 UTC | Q32 Bio Inc. QTTB · Entity 5594 | SaleCommon Stock | 265 | $24.20 | $6,413.00 |
DisclosureSEC source: 0000950170-24-096986 · ownership.xml · nonDerivative · entry 2 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,983 F3 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| March 25, 2024 Filed Aug 14, 2024 20:05 UTC | Q32 Bio Inc. QTTB · Entity 5594 | Exercise / conversionCommon Stock | 1,095 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-096986 · ownership.xml · nonDerivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer Common Stock. F2 · balance_after: The Issuer effected a 1-for-18 reverse stock split of its Common Stock on March 25, 2024. The amounts reported on this Form 4 have been adjusted to reflect the reverse stock split. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:17 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionStock Option (Right to Buy) · Derivative | 31,739 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001415889-24-003897 · form4-02152024_090236.xml · derivative · entry 2 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,739 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This fully-vested option award vested as to 1/48th of the total award on October 4, 2018 with 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:17 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 31,739 | $2.19 | $69,508.41 |
DisclosureSEC source: 0001415889-24-003897 · form4-02152024_090236.xml · nonDerivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2024 Filed Feb 15, 2024 21:33 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 13,037 | $0.57 | $7,445.43 |
DisclosureSEC source: 0000950170-24-015944 · ownership.xml · nonDerivative · entry 3 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,778 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of RSUs. F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $0.5710 to $0.5712. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3. Read SEC document |
| January 01, 2024 Filed Feb 15, 2024 21:33 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionRestricted Stock Units · Derivative | 19,140 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-015944 · ownership.xml · derivative · entry 5 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,720 Underlying: Common Stock · 19,140 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2022 so that such RSUs will become fully vested on January 1, 2025. The RSUs do not have an expiration date. F5 · derivative.expiration_date: The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2022 so that such RSUs will become fully vested on January 1, 2025. The RSUs do not have an expiration date. Read SEC document |
| January 01, 2024 Filed Feb 15, 2024 21:33 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionRestricted Stock Units · Derivative | 14,280 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-015944 · ownership.xml · derivative · entry 4 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,280 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The RSUs are fully vested and do not have an expiration date. F4 · derivative.expiration_date: The RSUs are fully vested and do not have an expiration date. Read SEC document |
| January 01, 2024 Filed Feb 15, 2024 21:33 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 19,140 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-015944 · ownership.xml · nonDerivative · entry 2 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| January 01, 2024 Filed Feb 15, 2024 21:33 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 14,280 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-015944 · ownership.xml · nonDerivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 22:14 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantOption (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000950170-23-028393 · ownership.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of June 14, 2024 or the day immediately prior to the date of the Issuer's next annual meeting of stockholders occurring after the date of grant, in either case subject to the Reporting Person continuing in service on the Board as a Non-Employee Director through such vesting date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:26 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 19,441 | $0.00 Strike: $12.46 | $0.00 |
DisclosureSEC source: 0001209191-23-037539 · doc4.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,441 Underlying: Common Stock · 19,441 shares Expires 2033-06-12 F1 · derivative.exercise_date: The option shall fully vest on June 13, 2024 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 10,616 | $1.39 | $14,761.55 |
DisclosureSEC source: 0000899243-23-001574 · doc4.xml · nonDerivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,395 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of restricted stock units. F2 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $1.38 to $1.41. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 2. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 21:36 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionRestricted Stock Units · Derivative | 19,140 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-000632 · doc4.xml · derivative · entry 4 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,860 Underlying: Common Stock · 19,140 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2022 so that such RSUs will become fully vested on January 1, 2025. The RSUs do not have an expiration date. F3 · derivative.expiration_date: The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2022 so that such RSUs will become fully vested on January 1, 2025. The RSUs do not have an expiration date. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 21:36 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionRestricted Stock Units · Derivative | 13,860 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-000632 · doc4.xml · derivative · entry 3 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,280 Underlying: Common Stock · 13,860 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. The RSUs do not have an expiration date. F2 · derivative.expiration_date: The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. The RSUs do not have an expiration date. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 21:36 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 19,140 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-000632 · doc4.xml · nonDerivative · entry 2 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 21:36 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 13,860 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-000632 · doc4.xml · nonDerivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 16:51 UTC | Akouos, Inc. AKUS · Entity 11574 | Disposition to issuerStock Option (right to buy) · Derivative | 16,000 | Not disclosed Strike: $4.21 | Not disclosed |
DisclosureSEC source: 0001104659-22-124141 · tm2231851-8_4seq1.xml · derivative · entry 3 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2032-06-22 F3 · price: At the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option to purchase Shares having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by (B) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option and (y) one CVR for each Share subject to such option immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option to purchase Shares having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by (B) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option and (y) one CVR for each Share subject to such option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 16:51 UTC | Akouos, Inc. AKUS · Entity 11574 | Disposition to issuerStock Option (right to buy) · Derivative | 12,100 | Not disclosed Strike: $7.38 | Not disclosed |
DisclosureSEC source: 0001104659-22-124141 · tm2231851-8_4seq1.xml · derivative · entry 2 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,100 shares Expires 2030-05-11 F3 · price: At the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option to purchase Shares having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by (B) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option and (y) one CVR for each Share subject to such option immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the effective time of the merger (the "Effective Time"), pursuant to the Merger Agreement, each outstanding option to purchase Shares having an exercise price less than $12.50 per Share, whether or not vested, was cancelled and converted into the right to receive (x) an amount in cash, without interest and less any applicable tax withholdings, equal to the product of (A) the total number of Shares subject to such option immediately prior to the Effective Time multiplied by (B) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option and (y) one CVR for each Share subject to such option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 16:51 UTC | Akouos, Inc. AKUS · Entity 11574 | OtherCommon Stock | 26,930 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-124141 · tm2231851-8_4seq1.xml · nonDerivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, these shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for (i) $12.50 per Share, net to the stockholder in cash, without interest (the "Cash Consideration") and less any applicable tax withholding, plus [Continued on Note 2] F2 · shares: [Continuation of Note 1] (ii) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Kearny Acquisition Corporation ("Merger Sub"), dated as of October 17, 2022, these shares of common stock, par value $0.0001 per share, of the Issuer ("Shares") were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for (i) $12.50 per Share, net to the stockholder in cash, without interest (the "Cash Consideration") and less any applicable tax withholding, plus [Continued on Note 2] F2 · price: [Continuation of Note 1] (ii) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement, dated as of November 30, 2022, by and among Parent, Merger Sub, Computershare Inc. and Computershare Trust Company, N.A. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 17:04 UTC | Akouos, Inc. AKUS · Entity 11574 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001104659-22-074830 · tm2219359-4_4seq1.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2032-06-22 F1 · derivative.exercise_date: This option was granted on June 23, 2022. The shares underlying the option will fully vest on the earlier of (i) June 23, 2023 and (ii) the date of the Issuer's 2023 annual meeting of stockholders. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 21:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $12.96 | $0.00 |
DisclosureSEC source: 0001209191-22-035075 · doc4.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2032-06-06 F1 · derivative.exercise_date: The option shall vest on June 7, 2023 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantRestricted Stock Units · Derivative | 58,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-008059 · doc4.xml · derivative · entry 2 TZIANABOS ARTHUR · CIK 0001586226 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,000 Underlying: Common Stock · 58,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date. F3 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2022 so that such RSUs will become fully vested on January 1, 2025. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units have no expiration date. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee Stock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $2.71 | $0.00 |
DisclosureSEC source: 0000899243-22-008059 · doc4.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2032-02-24 F1 · derivative.exercise_date: The option vests in 48 substantially equal monthly installments on the first day of each calendar month following January 1, 2022. Read SEC document |
| January 05, 2022 Filed Jan 12, 2022 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | SaleCommon Stock | 5,354 | $3.78 | $20,239.19 |
DisclosureSEC source: 0000899243-22-001743 · doc4.xml · nonDerivative · entry 2 TZIANABOS ARTHUR · CIK 0001586226 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,011 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of RSUs. F3 · price: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $3.78 to $3.80. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3. Read SEC document |
| January 01, 2022 Filed Jan 12, 2022 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionRestricted Stock Units · Derivative | 13,860 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001743 · doc4.xml · derivative · entry 3 TZIANABOS ARTHUR · CIK 0001586226 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,140 Underlying: Common Stock · 13,860 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The RSUs have vested and settled or will vest and settle, as applicable, as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. The RSUs do not have an expiration date. F4 · derivative.expiration_date: The RSUs have vested and settled or will vest and settle, as applicable, as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. The RSUs do not have an expiration date. Read SEC document |
| January 01, 2022 Filed Jan 12, 2022 21:05 UTC | Q32 Bio Inc. FIXX · Entity 5594 | Exercise / conversionCommon Stock | 13,860 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-001743 · doc4.xml · nonDerivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,365 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 16:34 UTC | Akouos, Inc. AKUS · Entity 11574 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $13.39 | $0.00 |
DisclosureSEC source: 0001104659-21-085755 · tm2120686-1_4seq1.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2031-06-23 F1 · derivative.exercise_date: This option was granted on June 24, 2021. The shares underlying the option will fully vest on the earlier of (i) June 24, 2022 and (ii) the date of the Issuer's 2022 annual meeting of stockholders. Read SEC document |
| June 08, 2021 Filed Jun 25, 2021 21:04 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 11,650 | $0.00 Strike: $40.37 | $0.00 |
DisclosureSEC source: 0001209191-21-043340 · doc4.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,650 Underlying: Common Stock · 11,650 shares Expires 2031-06-07 F1 · derivative.exercise_date: The option shall fully vest on June 8, 2022 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 22:28 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-21-013320 · doc4.xml · derivative · entry 3 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,447 Underlying: Common Stock · 10,000 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 1/48th of the total shares on October 4, 2018 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 22:28 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 10,000 | $60.67 | $606,652.00 |
DisclosureSEC source: 0001209191-21-013320 · doc4.xml · nonDerivative · entry 2 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 22:28 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 10,000 | $2.19 | $21,900.00 |
DisclosureSEC source: 0001209191-21-013320 · doc4.xml · nonDerivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 21:21 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantRestricted Stock Units · Derivative | 42,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-005455 · doc4.xml · derivative · entry 2 TZIANABOS ARTHUR · CIK 0001586226 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. F3 · derivative.expiration_date: The restricted stock units will vest and settle as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 21:21 UTC | Q32 Bio Inc. FIXX · Entity 5594 | GrantEmployee Stock Option (Right to Buy) · Derivative | 254,000 | $0.00 Strike: $13.78 | $0.00 |
DisclosureSEC source: 0000899243-21-005455 · doc4.xml · derivative · entry 1 TZIANABOS ARTHUR · CIK 0001586226 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,000 Underlying: Common Stock · 254,000 shares Expires 2031-02-05 F1 · derivative.exercise_date: The option vests in 48 equal monthly installments on the first day of each calendar month following January 1, 2021. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 22:09 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-060549 · doc4.xml · derivative · entry 6 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,447 Underlying: Common Stock · 20,000 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vested as to 1/48th of the total shares on October 4, 2018 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| November 23, 2020 Filed Nov 25, 2020 22:09 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 210 | $47.61 | $9,997.87 |
DisclosureSEC source: 0001209191-20-060549 · doc4.xml · nonDerivative · entry 5 TZIANABOS ARTHUR · CIK 0001586226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.47 to $47.71 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.